How to take aripiprazole. Before you start the treatment, read the manufacturer's printed information leaflet from inside the pack. It will give you more information about aripiprazole and it will also provide you with a full list of the side-effects which you may experience from taking it. Less information is available regarding the use of aripiprazole for treating disruptive behaviours and aggression. However, the available evidence is supportive. How should aripiprazole be taken? Aripiprazole is available as a tablet that is usually taken once daily with or without food. If you find that taking this medication causes stomach discomfort, try taking it with food. This. How to use Abilify. Read the Medication Guide and, if available, the Patient Information Leaflet provided by your pharmacist before you start taking aripiprazole and each time you get a refill. Detailed information on the antipsychotic drug aripiprazole (also known as Abilify or Abilify Maintena) including known interactions with other medication, potential side effects and withdrawal effects. General information about the safe and effective use of ABILIFY Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ABILIFY for Aripiprazole may also be used for purposes not listed in this medication guide. Important Information Aripiprazole may increase the risk of death in older adults with dementia -related conditions and is not approved for this use. The doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with aripiprazole. Read the information carefully and ask your doctor or pharmacist if you have any questions. This leaflet answers some common questions about aripiprazole. It does not contain all the available information. Abilify (aripiprazole is an antipsychotic medication. It works by changing the actions of chemicals in the brain. Abilify is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar I disorder (manic depression). In 2007, aripiprazole was approved by the FDA for the treatment of unipolar depression when used adjunctively with an antidepressant medication. That same year, BMS settled a case with the U.S. government in which it paid $515 million; the case covered several drugs but the focus was on BMS's off-label marketing of aripiprazole for children and older people with dementia.